James Jenkins

Artiklar

Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2025;13(4):e010434
MHC class II-mediated spontaneous rejection of breast carcinomas expressing model neoantigens.
Jenkins JW; Peña A; Castro SA; Hansen MJ; Van Keulen VP; Foster ST; Rios-Cruz PE; Yakubov J; Hinson DT; Olivier SM; Pavelko KD; Felts SJ; Johnson AJ; Pease LR
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2023;11(11):e007661
Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade.
Luo Y; Shreeder B; Jenkins JW; Shi H; Lamichhane P; Zhou K; Bahr DA; Kurian S; Jones KA; Daum JI; Dutta N; Necela BM; Cannon MJ; Block MS; Knutson KL
Article: IMMUNITY. 2019;51(3):491-507.e7
The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality.
Li C; Zhu B; Son YM; Wang Z; Jiang L; Xiang M; Ye Z; Beckermann KE; Wu Y; Jenkins JW; Siska PJ; Vincent BG; Prakash YS; Peikert T; Edelson BT; Taneja R; Kaplan MH; Rathmell JC; Dong H; Hitosugi T; Sun J